Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | CNR2 | P34972 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.51 |
| ▸ | CA2 | P00918 | 6/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8065958 | 0.85 | CA1 (0.52) | KDM4EKMT2ACA1CA2MEN1 | |
| SCHEMBL8062224 | 0.82 | CA1 (0.56) | KDM4ECA1CA2MAPT | |
| SCHEMBL8065959 | 0.81 | HPGD (0.67) | HPGDKDM4EKMT2AGAACA1 | |
| SCHEMBL8051169 | 0.80 | KMT2A (0.59) | HPGDKMT2AGAACA1CA2 | |
| SCHEMBL15881063 | 0.79 | CA1 (0.57) | HPGDKMT2ACA1CA2LMNA | |
| SCHEMBL18434389 | 0.77 | HPGD (0.77) | HPGDKDM4EKMT2AGAAHSD17B10 | |
| SCHEMBL21183474 | 0.77 | POLB (0.50) | KDM4EKMT2AHSD17B10CA1CA2 | |
| SCHEMBL10324045 | 0.76 | KDM4E (1.00) | HPGDKDM4EKMT2AGAAHSD17B10 | |
| SCHEMBL8067660 | 0.75 | POLB (0.62) | KDM4EKMT2AHSD17B10MEN1MAPT | |
| SCHEMBL17359125 | 0.75 | KDM4E (0.47) | KDM4EKMT2AHSD17B10CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9617208-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| EP-2190814-B1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | UNIV JOHNS HOPKINS (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2504003-B1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. | 2016-03-24 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-11-26 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115064-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-08-25 | — | — | US | disclosed |
| US-20140194416-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2012-10-11 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227639-B2 | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | CARDIOXYL PHARMACEUTICALS (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2011063339-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011063400-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2009-06-25 | — | — | US | disclosed |
| WO-2009042970-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | JOHNS HOPKINS UNIVERSITY (US) | 2009-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081951-A1 | NITROXYL DONORS FOR THE TREATMENT OF PULMONARY HYPERTENSION | NOS2, NOS3, NOS1 | HPGD 17/4885KDM4E 931/4885KMT2A 2073/4885 |
| US-20120258965-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | HPGD 24/4885KDM4E 2974/4885KMT2A 4724/4885 |
| US-20090163487-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | HPGD 24/4885KDM4E 2974/4885KMT2A 4724/4885 |
| US-20110160200-A1 | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension | NOS2, NOS3, NOS1 | HPGD 22/4885KDM4E 817/4885KMT2A 1142/4885 |
| US-20140194416-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | HPGD 24/4885KDM4E 2974/4885KMT2A 4724/4885 |
| US-20150336880-A1 | N-HYDROXYLSULFONAMIDE DERIVATIVES AS NEW PHYSIOLOGICALLY USEFUL NITROXYL DONORS | TNNI3, TNNC1, NME4 | HPGD 24/4885KDM4E 2974/4885KMT2A 4724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.